Zoster Treatment Market Size

Zoster Treatment Market size is poised to witness over 13.8% CAGR during the forecast period i.e., between 2024-2036.

The growth of the market can be primarily attributed to the high prevalence of the sickness and its increasing commonness among older populations. According to the Centers for Disease Control and Prevention, every year, a total of one million cases of herpes zoster occurs in the United States alone. The incidence of the disease among elderly population of 60 years and above is 1 case per 100 in the country.

In addition to these, the rising introduction of vaccines and medications for self-treatment, with the aim to opt for hospitalization only when of utmost necessity, is also a crucial factor expected to drive market growth in the upcoming years. Furthermore, upsurge in investments by prominent market players to develop effective and improved treatment for cutaneous viral infections is projected to offer profitable opportunities to the zoster treatment market in the near future.

Frequently Asked Questions (FAQ)

The major factors driving market growth are high prevalence of zoster globally and rising introduction of vaccines and medications for self-treatment.

The market is anticipated to attain a CAGR of ~14% over the forecast period, i.e., 2022 â€“ 2030.

High cost of zoster treatment is estimated to hamper the market growth.

Asia Pacific will provide more business opportunities for market growth owing to the growing occurrence of herpes zoster, and rising initiatives by governmental and non-governmental organizations associated with vaccination drives.

The major players in the market are Valeant Pharmaceuticals North America, LLC, Merck & Co., Inc., Abbott Laboratories, Teva Pharmaceutical Ltd, and others.

Zoster Treatment Market Size